Pfizer Downplays Risk Of Tofacitinib Panel Review As It Pushes Focus On Innovation
This article was originally published in The Pink Sheet Daily
Executive Summary
Capital allocation and business re-structuring dominated the conversation during Pfizer’s Q1 earnings call –its first full quarter without Lipitor exclusivity, even as the company waits for near-term regulatory decisions on key compounds.